![Patrick Dolezal](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Mr. Patrick E.
Dolezal is a Senior Research Analyst at LifeSci Capital LLC.
He focuses on emerging biotechnology and pharmaceutical companies.
His coverage universe includes a diverse range of therapeutic areas, which include gene therapy, gene editing, and hepatology.
He received his undergraduate degree from Indiana University and a graduate degree from New York University.
Postes actifs de Patrick Dolezal
Sociétés | Poste | Début |
---|---|---|
LifeSci Capital LLC
![]() LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank based in New York, NY. LifeSci Capital LLC provides financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. The company also has a highly regarded team of analysts who generate differentiated, proprietary research and cover companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Dan Alan Wychulis has been the CEO of the company since 2024. | Analyst-Equity | 01/06/2015 |
Formation de Patrick Dolezal
New York University | Graduate Degree |
Indiana University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
LifeSci Capital LLC
![]() LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank based in New York, NY. LifeSci Capital LLC provides financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. The company also has a highly regarded team of analysts who generate differentiated, proprietary research and cover companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Dan Alan Wychulis has been the CEO of the company since 2024. | Finance |